(ESSITY-B) Essity (publ) - Ratings and Ratios
Hygiene Products, Health Products, Consumer Goods, Professional Hygiene
ESSITY-B EPS (Earnings per Share)
ESSITY-B Revenue
Description: ESSITY-B Essity (publ)
Essity AB (publ) is a leading global hygiene and health company operating across multiple segments, including Health & Medical, Consumer Goods, and Professional Hygiene. The company offers a diverse range of products and services, catering to various customer needs, from personal care and hygiene to medical and professional cleaning solutions.
The Health & Medical segment provides specialized products, such as incontinence care, wound care, and compression therapy, under well-known brands like TENA, Leukoplast, and JOBST. The Consumer Goods segment offers a broad portfolio of personal care products, including feminine hygiene, baby care, and adult diapers, under brands like Libero, Libresse, and Bodyform. Meanwhile, the Professional Hygiene segment delivers high-quality cleaning and hygiene solutions to various industries and public venues through the Tork brand.
From a financial perspective, Essity AB (publ) has demonstrated a stable presence in the market, with a market capitalization of 184.37 billion SEK. Key performance indicators (KPIs) such as Return on Equity (RoE) of 15.04% indicate a relatively strong profitability. The companys forward Price-to-Earnings (P/E) ratio of 13.40 suggests a moderate valuation. Additionally, Essitys dividend yield and payout ratio could be analyzed to assess its attractiveness to income-seeking investors.
To further evaluate Essitys performance, one could examine its revenue growth, gross margin, and operating margin. The companys ability to maintain a competitive edge in the personal care and hygiene markets, as well as its capacity to innovate and expand its product offerings, will be crucial in driving future growth. Furthermore, analyzing Essitys cash flow generation, debt-to-equity ratio, and other financial metrics can provide a more comprehensive understanding of its financial health and stability.
ESSITY-B Stock Overview
| Market Cap in USD | 18,527m |
| Sub-Industry | Personal Care Products |
| IPO / Inception |
ESSITY-B Stock Ratings
| Growth Rating | -21.4% |
| Fundamental | 68.8% |
| Dividend Rating | 59.9% |
| Return 12m vs S&P 500 | -27.0% |
| Analyst Rating | - |
ESSITY-B Dividends
| Dividend Yield 12m | 3.05% |
| Yield on Cost 5y | 3.27% |
| Annual Growth 5y | 4.40% |
| Payout Consistency | 99.4% |
| Payout Ratio | 44.2% |
ESSITY-B Growth Ratios
| Growth Correlation 3m | -71.9% |
| Growth Correlation 12m | -89.4% |
| Growth Correlation 5y | 49.4% |
| CAGR 5y | 0.28% |
| CAGR/Max DD 5y | 0.01 |
| Sharpe Ratio 12m | 0.20 |
| Alpha | -16.27 |
| Beta | -0.140 |
| Volatility | 19.17% |
| Current Volume | 1316.7k |
| Average Volume 20d | 1054.8k |
| Stop Loss | 247.9 (-3%) |
| Signal | 0.41 |
Piotroski VR‑10 (Strict, 0-10) 6.0
| Net Income (12.29b TTM) > 0 and > 6% of Revenue (6% = 8.59b TTM) |
| FCFTA 0.05 (>2.0%) and ΔFCFTA -4.40pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 11.79% (prev 9.70%; Δ 2.09pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.09 (>3.0%) and CFO 15.04b > Net Income 12.29b (YES >=105%, WARN >=100%) |
| Net Debt (-3.93b) to EBITDA (25.69b) ratio: -0.15 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.45 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (691.5m) change vs 12m ago -1.48% (target <= -2.0% for YES) |
| Gross Margin 32.66% (prev 30.58%; Δ 2.08pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 81.92% (prev 83.16%; Δ -1.24pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 12.40 (EBITDA TTM 25.69b / Interest Expense TTM 1.48b) >= 6 (WARN >= 3) |
Altman Z'' 3.75
| (A) 0.10 = (Total Current Assets 54.27b - Total Current Liabilities 37.38b) / Total Assets 167.41b |
| (B) 0.43 = Retained Earnings (Balance) 71.95b / Total Assets 167.41b |
| (C) 0.10 = EBIT TTM 18.32b / Avg Total Assets 174.86b |
| (D) 0.94 = Book Value of Equity 80.80b / Total Liabilities 86.21b |
| Total Rating: 3.75 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 68.79
| 1. Piotroski 6.0pt = 1.0 |
| 2. FCF Yield 3.58% = 1.79 |
| 3. FCF Margin 5.52% = 1.38 |
| 4. Debt/Equity 0.63 = 2.30 |
| 5. Debt/Ebitda 1.99 = 0.01 |
| 6. ROIC - WACC 11.90% = 12.50 |
| 7. RoE 14.82% = 1.24 |
| 8. Rev. Trend -80.14% = -4.01 |
| 9. Rev. CAGR -5.65% = -0.94 |
| 10. EPS Trend 40.46% = 1.01 |
| 11. EPS CAGR 27.94% = 2.50 |
What is the price of ESSITY-B shares?
Over the past week, the price has changed by +0.12%, over one month by +4.33%, over three months by -8.81% and over the past year by -14.58%.
Is Essity (publ) a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ESSITY-B is around 225.31 SEK . This means that ESSITY-B is currently overvalued and has a potential downside of -11.85%.
Is ESSITY-B a buy, sell or hold?
What are the forecasts/targets for the ESSITY-B price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 288.8 | 13% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 241.8 | -5.4% |
ESSITY-B Fundamental Data Overview
Market Cap SEK = 176.45b (176.45b SEK * 1.0 SEK.SEK)
CCE Cash And Equivalents = 6.70b SEK (Cash And Short Term Investments, last quarter)
P/E Trailing = 14.4093
P/E Forward = 15.1286
P/S = 1.2318
P/B = 2.1671
P/EG = 3.1535
Beta = 0.279
Revenue TTM = 143.24b SEK
EBIT TTM = 18.32b SEK
EBITDA TTM = 25.69b SEK
Long Term Debt = 48.82b SEK (from nonCurrentLiabilitiesTotal, last quarter)
Short Term Debt = 2.39b SEK (from shortTermDebt, last quarter)
Debt = 51.21b SEK (Calculated: Short Term 2.39b + Long Term 48.82b)
Net Debt = -3.93b SEK (from netDebt column, last quarter)
Enterprise Value = 220.95b SEK (176.45b + Debt 51.21b - CCE 6.70b)
Interest Coverage Ratio = 12.40 (Ebit TTM 18.32b / Interest Expense TTM 1.48b)
FCF Yield = 3.58% (FCF TTM 7.91b / Enterprise Value 220.95b)
FCF Margin = 5.52% (FCF TTM 7.91b / Revenue TTM 143.24b)
Net Margin = 8.58% (Net Income TTM 12.29b / Revenue TTM 143.24b)
Gross Margin = 32.66% ((Revenue TTM 143.24b - Cost of Revenue TTM 96.46b) / Revenue TTM)
Tobins Q-Ratio = 2.73 (Enterprise Value 220.95b / Book Value Of Equity 80.80b)
Interest Expense / Debt = 0.47% (Interest Expense 243.0m / Debt 51.21b)
Taxrate = 26.47% (from yearly Income Tax Expense: 4.33b / 16.36b)
NOPAT = 13.47b (EBIT 18.32b * (1 - 26.47%))
Current Ratio = 1.45 (Total Current Assets 54.27b / Total Current Liabilities 37.38b)
Debt / Equity = 0.63 (Debt 51.21b / last Quarter total Stockholder Equity 80.80b)
Debt / EBITDA = 1.99 (Net Debt -3.93b / EBITDA 25.69b)
Debt / FCF = 6.47 (Debt 51.21b / FCF TTM 7.91b)
Total Stockholder Equity = 82.95b (last 4 quarters mean)
RoA = 7.34% (Net Income 12.29b, Total Assets 167.41b )
RoE = 14.82% (Net Income TTM 12.29b / Total Stockholder Equity 82.95b)
RoCE = 13.91% (Ebit 18.32b / (Equity 82.95b + L.T.Debt 48.82b))
RoIC = 16.24% (NOPAT 13.47b / Invested Capital 82.95b)
WACC = 4.34% (E(176.45b)/V(227.66b) * Re(5.50%)) + (D(51.21b)/V(227.66b) * Rd(0.47%) * (1-Tc(0.26)))
Shares Correlation 5-Years: -66.70 | Cagr: -0.39%
Discount Rate = 5.50% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
[DCF Debug] Terminal Value 76.60% ; FCFE base≈11.41b ; Y1≈10.24b ; Y5≈8.75b
Fair Price DCF = 251.9 (DCF Value 158.17b / Shares Outstanding 627.9m; 5y FCF grow -12.69% → 3.0% )
Revenue Correlation: -80.14 | Revenue CAGR: -5.65%
Rev Growth-of-Growth: 2.77
EPS Correlation: 40.46 | EPS CAGR: 27.94%
EPS Growth-of-Growth: -51.36